Evaluation of the effect of adding a mGlu2/3 orthosteric antagonist to a highly selective 5-HT2A antagonist on dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset
Objective: To determine whether the therapeutic effect of serotonin 2A (5-HT2A) receptor antagonism on dyskinesia and psychosis may be reversed by orthosteric antagonism of metabotropic…Epidemiologic And Clinical Features Of Psychiatric Disorders In Patients With Parkinson’s Disease – A Retrospective Cohort Study
Objective: We aimed to assess the average duration of Parkinson's disease at the time patient was diagnosed with specific neuropsychiatric disturbance, to study their prevalence…Non-Invasive Brain Stimulation for the Treatment of Psychiatric Symptoms in Parkinson’s Disease: A Systematic Review and Meta-analysis
Objective: This meta-analysis aims to assess the effect of NIBS technique for psychiatric symptoms in patients with PD. Background: Non-invasive brain stimulations (NIBS), especially repetitive…ER Visits and Hospitalizations Among Patients Treated with Pimavanserin or Other-AAPs for Parkinson’s Disease Psychosis: Analysis of Medicare beneficiaries
Objective: To examine health resource utilization (HRU) outcomes among PDP patients treated with PIMA vs. other AAPs. Background: Real-world analysis demonstrating pimavanserin (PIMA) benefits, the…Parkinson’s Disease, Cognition, Positive Symptoms and Medication Management
Objective: Explore the relationship between multi-domain cognitive testing and patient-reported psychiatric symptoms in PwPD to self-medication management capabilities. Background: Parkinson’s disease (PD) is a complex…Phantom boarder syndrome associated with experimentally-induced presence hallucinations in Parkinson’s disease
Objective: Measuring experimentally-induced presence hallucinations in patients with Parkinson’s disease phantom boarder phenomena. Background: Phantom boarder syndrome (PB) is described as the sensation that someone…Reduced Risk of Mortality and Antipsychotics in Parkinson’s Disease-Related Psychosis: Pimavanserin vs Off-Label Antipsychotics
Objective: Summarize the available data for the mortality risk associated with Parkinson’s disease (PD) psychosis (PDP) and pimavanserin. Background: PDP is associated with increased mortality…Parkinson’s Disease and Psychosocial Impact: Anxiety, Depression and Positive Symptoms
Objective: Explore the relationship between patient self-reported assessment of positive symptoms, depression, and anxiety in PwPD. Background: Parkinson’s disease (PD) is a complex neurodegenerative disorder…Risk of Long-term Care Admissions Among Medicare Patients Treated with Pimavanserin or Other Atypical Antipsychotics for Parkinson’s Disease Psychosis
Objective: To examine all-cause long-term care (LTC) admission risk among PDP patients treated with atypical antipsychotic (AAP). Background: Risk of LTC-admissions associated with off-label AAPs…Motor-Related and Cognition-Related Safety of Pimavanserin in Patients with Parkinson’s Disease Psychosis (PDP)
Objective: Evaluate motor- and cognition-related safety in pimavanserin-treated patients with PDP. Background: Pimavanserin, a selective 5-HT2A inverse agonist/antagonist, is the only US FDA-approved treatment for…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 12
- Next Page »